Genetic Technologies Ltd. ADR (GENE): Price and Financial Metrics
GET POWR RATINGS... FREE!
GENE Stock Price Chart Interactive Chart >
GENE Price/Volume Stats
| Current price | $1.14 | 52-week high | $2.85 |
| Prev. close | $1.14 | 52-week low | $0.95 |
| Day low | $1.11 | Volume | 16,900 |
| Day high | $1.16 | Avg. volume | 59,773 |
| 50-day MA | $1.20 | Dividend yield | N/A |
| 200-day MA | $1.49 | Market Cap | 17.54M |
Genetic Technologies Ltd. ADR (GENE) Company Bio
Genetic Technologies Ltd. is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. It operates through the USA and Australia geographical segments. The firm's product BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.
Latest GENE News From Around the Web
Below are the latest news stories about GENETIC TECHNOLOGIES LTD that investors may wish to consider to help them evaluate GENE as an investment opportunity.
Webinar - Dr Erika Spaeth to interview A/Prof Charles Siles on risk assessment tests for serious diseaseMELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies (ASX:GTG, NASDAQ:GENE), a global leader in guideline driven Genomics based tests in health, wellness and serious disease will be hosting an interview between Dr Erika Spaeth (PhD Director of Clinical & Scientific Affairs and GTG in the US) and Adjunct Professor Charles Siles Health (Executive Director and founder of Siles Health). A/Prof. Charles Siles, Obstetrician and Gynaecologist operates nine (9) clinics across Vic |
Genetype for Ovarian Cancer Published in Prestigious European Journal of Cancer PreventionMELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is delighted to announce the publication of a validation study evaluating the performance of the geneType ovarian cancer test. This 10 year prospective cohort study utilizes data from more than 190,000 women and has been published in the prestigious European Journal of Canc |
Genetic Technologies Announces Q1 FY23 Quarterly Results and Investor Webinar DetailsMELBOURNE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious disease has released its results for the quarter ended September 30, 2022 (Q1 FY23). Q1 FY23 Highlights: Revenue from customers of A$1.93 million for the quarter, up 375% from prior corresponding period (Q1 FY22), highlighting commercial progress with revenues anchoring from GTG’s |
Genetic Technologies Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)RedChip Companies will air a new interview with Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) ("Company", "GTG"), a global leader in genomics-based tests in health, wellness, and serious disease, on The RedChip Money Report® on Bloomberg TV, this Saturday, October 15, at 7 p.m. Eastern Time (ET). |
Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancerMELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the recent publication of a paper in the Journal of Precision Medicine authored by GTG science team members, Dr Erika Spaeth, Director of Clinical Affairs, Dr Richard Allman, Chief Scientific Officer, and Dr Gillian Dite, Senior Biostatistician. Publication highlig |
GENE Price Returns
| 1-mo | -5.00% |
| 3-mo | -24.00% |
| 6-mo | N/A |
| 1-year | -52.50% |
| 3-year | -39.60% |
| 5-year | -73.85% |
| YTD | -39.36% |
| 2021 | -47.78% |
| 2020 | 80.90% |
| 2019 | -9.54% |
| 2018 | -52.59% |
| 2017 | 7.41% |
Continue Researching GENE
Want to see what other sources are saying about Genetic Technologies Ltd's financials and stock price? Try the links below:Genetic Technologies Ltd (GENE) Stock Price | Nasdaq
Genetic Technologies Ltd (GENE) Stock Quote, History and News - Yahoo Finance
Genetic Technologies Ltd (GENE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...